Oral poliovirus vaccine in tropical Africa: greater impact on incidence of paralytic disease than expected from coverage surveys and seroconversion rates
- PMID: 3500802
- PMCID: PMC2491033
Oral poliovirus vaccine in tropical Africa: greater impact on incidence of paralytic disease than expected from coverage surveys and seroconversion rates
Abstract
During the first 5 years of a poliomyelitis control programme in Yaounde, Cameroon, a maximum of 35% of children aged 12-23 months were estimated to have received three doses of trivalent oral vaccine. Despite this low immunization coverage and low seroconversion rates, which were determined concurrently, the estimated incidence of paralytic poliomyelitis decreased by 85%.A detailed study of immunized children and of children living in the same households suggests that community spread of the vaccine virus and cross-immunity may have partly been responsible for the dramatic decrease in the incidence of paralytic disease, and that competing non-polio enterovirus infection was not a cause for the low seroconversion rates. These results suggest that immunization coverage and seroconversion rates alone are not sufficient criteria for determining the effectiveness of control programmes that use oral poliovirus vaccine in tropical Africa; surveillance of the incidence of paralytic disease must also be carried out.
Similar articles
-
Decision analysis in planning for a polio outbreak in the United States.Pediatrics. 2006 Aug;118(2):611-8. doi: 10.1542/peds.2005-2358. Pediatrics. 2006. PMID: 16882814
-
Immunization against poliomyelitis: risk/benefit/cost in a changing context.Dev Biol Stand. 1979;43:151-7. Dev Biol Stand. 1979. PMID: 230106
-
Combined live and inactivated poliovirus vaccine to control poliomyelitis in a developing country--five years after.Dev Biol Stand. 1986;65:137-43. Dev Biol Stand. 1986. PMID: 3556771
-
[Worldwide eradication of poliomyelitis].Wien Klin Wochenschr. 2001 Oct 30;113(20-21):839-45. Wien Klin Wochenschr. 2001. PMID: 11732120 Review. German.
-
Immunoprophylaxis in poliomyelitis.J Commun Dis. 1984 Mar;16(1):38-42. J Commun Dis. 1984. PMID: 12055784 Review.
Cited by
-
A spatial model of Wild Poliovirus Type 1 in Kano State, Nigeria: calibration and assessment of elimination probability.BMC Infect Dis. 2016 Sep 29;16(1):521. doi: 10.1186/s12879-016-1817-3. BMC Infect Dis. 2016. PMID: 27681708 Free PMC article.
-
[Increasing the efficiency of a mobile EPI strategy using injectable polio vaccine in Africa].Med Trop Sante Int. 2023 Jun 2;3(2):mtsi.v3i2.2023.344. doi: 10.48327/mtsi.v3i2.2023.344. eCollection 2023 Jun 30. Med Trop Sante Int. 2023. PMID: 37525682 Free PMC article. French.
-
Mucosal COVID-19 vaccines: Risks, benefits and control of the pandemic.World J Virol. 2022 Sep 25;11(5):221-236. doi: 10.5501/wjv.v11.i5.221. World J Virol. 2022. PMID: 36188733 Free PMC article. Review.
-
Serological and virological assessment of oral and inactivated poliovirus vaccines in a rural population in Kenya.Bull World Health Organ. 1992;70(1):93-103. Bull World Health Organ. 1992. PMID: 1568283 Free PMC article.
-
Preeradication vaccine policy options for poliovirus infection and disease control.Risk Anal. 2013 Apr;33(4):516-43. doi: 10.1111/risa.12019. Epub 2013 Mar 5. Risk Anal. 2013. PMID: 23461599 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical